Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Inflammation damages sweat ducts, causing sweat gland injury.

A woman with skin and joint issues progressed from one type of lupus to another, highlighting the need to recognize complex conditions.

Spironolactone helps reduce pain and lesions in hidradenitis suppurativa patients, and lower doses are also effective.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.

Low quality of life and high HSS-29 scores increase risk of losing patients during treatment.

Hidradenitis suppurativa severely impacts quality of life, especially with severe symptoms and certain comorbidities, and current treatments don't significantly improve it.

Different autoantibody groups in pediatric SLE are linked to specific symptoms and disease outcomes.

People with alopecia areata often have higher rates of allergies and autoimmune diseases.

Men with severe hair loss may have a higher risk of heart disease.

Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

A new treatment plan helps manage folliculitis decalvans effectively.

Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.

All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.

Budesonide alone is less effective than standard treatment for autoimmune hepatitis.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.